Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female at least 1 month or older at screening.~2. Clinical diagnosis of CTX with biochemical confirmation.~3. Women of childbearing potential must agree to the use of one highly reliable method of contraception during the study, plus one additional barrier method during sexual activity.~4. Males must be surgically sterile, or males and their sexual partners must together agree to use medically accepted methods of contraception that are considered highly reliable during the course of the study.~Exclusion Criteria:~1. Genetic testing does not confirm CTX.~2. Malabsorption disorder or confounding inflammatory gastrointestinal condition (for example, irritable bowel syndrome).~3. Documented history of heart failure.~4. Treated with medications which impact bile acid absorption such as bile acid sequestering agents (eg, cholestyramine, colestipol, aluminum-based antacids.~5. Treated with cholic acid medication.~6. Female patient who is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.~7. Positive at screening for the human immunodeficiency virus (HIV) or markers indicating acute or chronic hepatitis B infection or hepatitis C infection.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adult Cohort (Type: EXPERIMENTAL): Patients in the adult cohort will participate in a randomized, double-blind, placebo-controlled, 2 period × 2-treatment crossover study with rescue medication and open-label run-in to assess the efficacy and safety of CDCA.
- Pediatric Cohort (Type: EXPERIMENTAL): Pediatric cohort patients (≥1 month and \<16 years) will participate in a 24-week, open-label cohort with an 8-week titration period and a 16-week treatment period at the tolerated dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).